drugset / Trial / NCT05842512
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
RandomizedParallel-groupTriple-blindTreatment
Summary
Evaluate efficacy and safety of ADI-PEG 20 in patients with NASH
Timeline
- Start
- 2023-09-13
- Primary completion
- 2027-12-31
- Completion
- 2028-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegargiminase | Protein / enzyme biologic | 36 mg/m2 | Intramuscular |